MYOV / Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the number more_horizontal

Myovant secured FDA approval for Myfembree for the treatment of endometriosis in early August. The approval clears the regulatory overhang on the stoc more_horizontal

Myovant Sciences Ltd. (NYSE:MYOV ) Q1 2022 Results Conference Call July 27, 2022 5:00 PM ET Company Participants Uneek Mehra - Chief Financial & Busin more_horizontal

Myovant has performed well since the regulatory setback in April. The PDUFA date for the sNDA for Myfembree has been extended by three months and Orgo more_horizontal

Myovant Sciences (MYOV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions more_horizontal

Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) announced an update for an sNDA for MYFEMBREE, which is designed to manage severe to moderate more_horizontal

Shares of Myovant Sciences plunged this week after a regulatory setback for Myfembree. No reasons were provided by the FDA yet, and the deficiency let more_horizontal

The FDA has identified deficiencies with Myovant's regulatory filing for Myfembree. more_horizontal